Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

Rhea-AI Summary

Replimune Group, a clinical-stage biotechnology company based in Woburn, MA, announced that CEO Philip Astley-Sparke will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. This event will highlight Replimune's innovative work in developing tumor-directed oncolytic immunotherapies through its proprietary RPx platform. This platform, leveraging a potent HSV-1 backbone, aims to enhance anti-tumor immune response. A webcast of the presentation will be accessible on their website, with a replay available for 30 days post-event.

WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

FAQ

What is Replimune Group presenting at the SVB Securities Global Biopharma Conference?

Replimune Group will showcase its tumor-directed oncolytic immunotherapies during a presentation by CEO Philip Astley-Sparke at the SVB Securities Global Biopharma Conference on February 14, 2023.

When is Philip Astley-Sparke's presentation at the conference?

Philip Astley-Sparke's presentation is scheduled for February 14, 2023, at 9:20 AM ET.

How can I access the Replimune Group conference presentation?

The presentation can be accessed via a live webcast in the Investors section of Replimune’s website, with a replay available for 30 days after the conference.

What is the RPx platform developed by Replimune?

The RPx platform is based on a potent HSV-1 backbone that enhances the immunogenic response to cancer, aiming to transform cancer treatment.

Where is Replimune Group located?

Replimune Group is headquartered in Woburn, Massachusetts.